CA2661492A1 - Hcv fusion polypeptides - Google Patents

Hcv fusion polypeptides Download PDF

Info

Publication number
CA2661492A1
CA2661492A1 CA002661492A CA2661492A CA2661492A1 CA 2661492 A1 CA2661492 A1 CA 2661492A1 CA 002661492 A CA002661492 A CA 002661492A CA 2661492 A CA2661492 A CA 2661492A CA 2661492 A1 CA2661492 A1 CA 2661492A1
Authority
CA
Canada
Prior art keywords
amino acids
hcv
sequence
core
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661492A
Other languages
English (en)
French (fr)
Inventor
Michael Houghton
Yin-Ling Lin
Angelica Medina-Selby
Doris Coit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2661492A1 publication Critical patent/CA2661492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002661492A 2006-08-25 2007-08-27 Hcv fusion polypeptides Abandoned CA2661492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84016206P 2006-08-25 2006-08-25
US60/840,162 2006-08-25
PCT/US2007/018940 WO2008024518A2 (en) 2006-08-25 2007-08-27 Hcv fusion polypeptides

Publications (1)

Publication Number Publication Date
CA2661492A1 true CA2661492A1 (en) 2008-02-28

Family

ID=38969483

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002661492A Abandoned CA2661492A1 (en) 2006-08-25 2007-08-27 Hcv fusion polypeptides

Country Status (5)

Country Link
US (1) US8216590B2 (enExample)
EP (1) EP2061888A2 (enExample)
JP (2) JP5474547B2 (enExample)
CA (1) CA2661492A1 (enExample)
WO (1) WO2008024518A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
CA2986342C (en) 2015-07-07 2024-04-02 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
BR102018071672A2 (pt) * 2018-10-22 2021-11-16 Fundação Oswaldo Cruz Polipeptídeo, cassete de expressão, vetor de expressão, célula hospedeira, kit para triagem imunológica de hcv e/ou diagnóstico de hepatite c, composição, uso de pelo menos um polipeptídeo, e, métodos para produzir um polipeptídeo, para triagem imunológica de hcv e para o diagnóstico de hepatite c

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
KR0185426B1 (ko) 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
US6054424A (en) 1998-04-15 2000-04-25 Church & Dwight Co., Inc. Process for the production of a liquid laundry detergent composition of desired viscosity containing nonionic and anionic surfactants
EP1113777B1 (en) 1998-06-09 2007-01-10 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
ES2411096T3 (es) 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
DE60036881T2 (de) * 1999-11-24 2008-07-10 Novartis Vaccines and Diagnostics, Inc., Emeryville Neues nichtstrukturelles hcv-polypeptid
PL374349A1 (en) * 2002-07-02 2005-10-17 Chiron Corporation Hcv fusion proteins with modified ns3 domains
EP1576125A4 (en) 2002-10-25 2008-09-03 Novartis Vaccines & Diagnostic ACTIVATION OF SPECIFIC HCV LYMPHOCYTES
NZ551319A (en) 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
EP1799868B1 (en) 2004-08-27 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Hcv non-structural protein mutants and uses thereof

Also Published As

Publication number Publication date
US8216590B2 (en) 2012-07-10
JP2014036675A (ja) 2014-02-27
EP2061888A2 (en) 2009-05-27
JP2010501580A (ja) 2010-01-21
JP5474547B2 (ja) 2014-04-16
WO2008024518A2 (en) 2008-02-28
WO2008024518A3 (en) 2008-04-10
US20100092503A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
US20100291134A1 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
US20090098153A1 (en) Activation of HCV-specific T cells
AU2003248818A1 (en) Hcv fusion proteins with modified ns3 domains
US7439058B2 (en) HBV/HCV virus-like particle
EP1233783B1 (en) Hbv/hcv virus-like particle
CA2636032C (en) Activation of hcv-specific t cells
US8216590B2 (en) HCV fusion polypeptides
US20050074465A1 (en) HCV fusion proteins with modified NS3 domains
WO2004039950A2 (en) Activation of hcv-specific cells
EP1535628B1 (en) Hbv/hcv virus-like particle
WO2007041432A2 (en) Cross-neutralization of hcv with recombinant proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150827